A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UNI91103 INTRANASAL ADMINISTRATION IN ADULTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC COVID-19
Latest Information Update: 28 Feb 2022
At a glance
- Drugs Niclosamide (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms PREVENT
- Sponsors UNION Therapeutics
- 13 Feb 2022 Status changed from recruiting to discontinued.
- 21 Oct 2021 Planned End Date changed from 30 Nov 2021 to 30 Dec 2021.
- 21 Oct 2021 Planned primary completion date changed from 30 Oct 2021 to 30 Nov 2021.